Purdue University: Biotech Company Eradivir Closes $10.25M Series A Funding Round to Complete Phase 2a Study of Influenza Therapeutic
September 25, 2024
September 25, 2024
WEST LAFAYETTE, Indiana, Sept. 25 (TNSres) -- Purdue University issued the following news release:
Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round. The funding will be used to conduct a Phase 2a challenge study of its EV25 influenza treatment.
CEO Martin Low said EV25 consistently outperforms the current standard of care for influenza in preclinical models.
"Within 24 h . . .
Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round. The funding will be used to conduct a Phase 2a challenge study of its EV25 influenza treatment.
CEO Martin Low said EV25 consistently outperforms the current standard of care for influenza in preclinical models.
"Within 24 h . . .